In addition, nearly one in four isolates in 2010 were resistant to trimethoprim-sulfamethoxazole, the second most commonly prescribed drug for this infection.
“Our study is important because it shows that E. coli resistance to two common drugs to treat UTIs rose substantially over the last decade. For patients, this will ultimately translate into more expensive and sometimes more complex antimicrobial treatments. What is more concerning, however, is the lack of new antimicrobial drug development which has been declining for decades,” said the primary author of the study.
Related Articles on Antimicrobial Resistance:
Methodologies Used to Determine LOS From Infection Are Inconsistent
Infectious Disease Societies Call for Increased Focus on Antimicrobial Stewardship
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
